(888) 440-0954


Cancer Immunotherapy Biomarkers: Four Trends to Watch

  • Using state of the art technologies for biomarker development
  • Validating PD-L1 as a biomarker of response
  • Linking tumor mutation burden to response rate
  • Leveraging the tumor microenvironment to direct therapeutic development

Considering Genomic Research?

    Fields marked in * is mandatory to fill

    2024 © MedGenome • All Rights Reserved
    Request a Quote